CALC

CalciMedica Inc

Add to Watchlist

Advanced Chart

2.870

+0.08(2.867%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.9703

Open

2.9703

VWAP

2.86

Vol

17.50K

Mkt Cap

40.10M

Low

2.810

Amount

50.10K

EV/EBITDA(TTM)

Total Shares

10.75M

29.53M

EV/OCF(TTM)

P/S(TTM)

CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

-0.412

-17.5%

-0.380

-68.85%

-0.510

+41.67%

Estimates Revision

The market is revising No Change the revenue expectations for CalciMedica, Inc. (CALC) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 63.07%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+63.07%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CALC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CALC is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.870

Low

16.00

Averages

16.00

High

16.00

Current: 2.870

Low

16.00

Averages

16.00

High

16.00

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-04-01

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-04-01

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2025-03-04

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2025-03-04

Reiterates

Strong Buy

Reason

LUCID CAPITAL MARKETS

Dev Prasad

Strong Buy

Initiates

$13

2024-12-17

Reason

LUCID CAPITAL MARKETS

Dev Prasad

Price Target

$13

2024-12-17

Initiates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$16

2024-11-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$16

2024-11-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Maintains

$20 → $16

2024-11-04

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$20 → $16

2024-11-04

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for CalciMedica Inc (CALC.O) is -1.51, compared to its 5-year average forward P/E of -1.87. For a more detailed relative valuation and DCF analysis to assess CalciMedica Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.87

Current PE

-1.51

Overvalued PE

-0.87

Undervalued PE

-2.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.61

Current EV/EBITDA

-0.90

Overvalued EV/EBITDA

-0.02

Undervalued EV/EBITDA

-1.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

FY2025Q2

YoY :

+1.41%

-6.62M

Operating Profit

FY2025Q2

YoY :

+50.63%

-5.96M

Net Income after Tax

FY2025Q2

YoY :

+11.11%

-0.40

EPS - Diluted

FY2025Q2

YoY :

-1.72%

-6.68M

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.6K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

180.9K

USD

Months

3-6

1.7K

USD

Months

6-9

12.7K

USD

Months

0-12

1.2M

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

300.0K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

3.6K

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

180.9K

USD

Months

3-6

1.7K

USD

Months

6-9

12.7K

USD

Months

0-12

1.2M

USD

Months

CALC News & Events

Events Timeline

2025-08-12 (ET)

2025-08-12

07:02:04

CalciMedica reports Q2 EPS (40c) vs. (36c) last year

2025-06-25 (ET)

2025-06-25

07:03:09

CalciMedica announces publication on Kourage trial in AJN

2025-03-27 (ET)

2025-03-27

07:02:14

CalciMedica says cash sufficient to fund operating plan into mid-2026

News

9.5

08-12PRnewswire

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

1.0

07-08Newsfilter

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

9.0

06-25Newsfilter

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure